Zheng Bin, Peng Wenchang, Gan Lin, Guo Mingming, Wang Shuchao, Zhang Xiao-Dong, Ming Dong
Academy of Medical Engineering and Translational Medicine, Tianjin Key Laboratory of Brain Science and Neural Engineering, Tianjin University, 92 Weijin Road, Nankai District, Tianjin, 300072, China.
School of Precision Instrument and Opto-electronics Engineering, Tianjin University, Tianjin, 300072, China.
Bioact Mater. 2021 Apr 13;6(11):3879-3891. doi: 10.1016/j.bioactmat.2021.04.002. eCollection 2021 Nov.
The conventional immunoadjuvants in vaccine have weak effect on stimulating antigen presentation and activating anti-tumor immunity. Unexpectedly, we discovered that non-pathogenic Sendai virus (SeV) could activate antigen-presenting cells (APCs) represented by dendritic cells (DCs). Here, we designed an injectable SeV-based hydrogel vaccine (SHV) to execute multi-channel recruitment and stimulation of DCs for boosting the specific immune response against tumors. After the release of the NIR-triggered antigens from tumor cells, dendritic cells around the vaccine efficiently transport the antigens to lymph nodes and present them to T lymphocytes, thereby inducing systemic anti-tumor immune memory. Our findings demonstrated that the SHV with excellent universality, convenience and flexibility has achieved better immune protection effects in inhibiting the occurrence of melanoma and breast cancer. In conclusion, the SHV system might serve as the next generation of personalized anti-tumor vaccines with enhanced features over standard vaccination regimens, and represented an alternative way to suppress tumorigenesis.
疫苗中的传统免疫佐剂在刺激抗原呈递和激活抗肿瘤免疫方面效果较弱。出乎意料的是，我们发现非致病性仙台病毒（SeV）可以激活以树突状细胞（DC）为代表的抗原呈递细胞（APC）。在此，我们设计了一种基于SeV的可注射水凝胶疫苗（SHV），以实现对DC的多通道募集和刺激，从而增强针对肿瘤的特异性免疫反应。肿瘤细胞释放近红外触发抗原后，疫苗周围的树突状细胞有效地将抗原转运至淋巴结并呈递给T淋巴细胞，从而诱导全身性抗肿瘤免疫记忆。我们的研究结果表明，具有出色通用性、便利性和灵活性的SHV在抑制黑色素瘤和乳腺癌发生方面取得了更好的免疫保护效果。总之，SHV系统可能作为下一代个性化抗肿瘤疫苗，比标准疫苗接种方案具有更强的功能特性，并且代表了一种抑制肿瘤发生的替代方法。
